Mechanism of action

SARCLISA: A CD38-directed cytolytic antibody

Selective binding triggers multiple mechanisms, leading to the death of CD38-expressing tumor cells1

Immune effector mechanisms

SARCLISA activates immune effector mechanisms, including ADCP, CDC, and ADCC.1

SARCLISA mechanism of action: SARCLISA binds to myeloma cells via CD38

Key for SARCLISASARCLISA

Key for CD38CD38

NK cells

SARCLISA can activate NK cells in the absence of CD38-positive target tumor cells.1

Tregs

SARCLISA suppresses CD38-positive Tregs.1

Apoptosis

SARCLISA induces tumor cell death.1

Inhibits enzymatic activity

SARCLISA inhibits the ADP-ribosyl cyclase activity of CD38.1

Key for SARCLISASARCLISA

Key for CD38CD38

Immune effector mechanisms

SARCLISA activates immune effector mechanisms, including ADCP, CDC, and ADCC.1

Apoptosis

SARCLISA induces direct tumor cell death.1

Inhibits enzymatic activity

SARCLISA inhibits the ADP-ribosyl cyclase activity of CD38.1

NK cells

SARCLISA can activate NK cells in the absence of CD38-positive target tumor cells.1

Tregs

SARCLISA suppresses CD38-positive Tregs.1

The combination of SARCLISA and pomalidomide enhanced ADCC activity and direct tumor cell killing compared to SARCLISA alone in vitro.1

Image is not to scale.

ADCC=antibody-dependent cell-mediated cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; ADP=adenosine diphosphate; C1q=complement component 1q; CDC=complement-dependent cytotoxicity; MAC=membrane attack complex; NK=natural killer; Treg=regulatory T cell.

View Trial Design